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Summary
Objective: To develop an enzyme linked immunosorbent assay (ELISA) to quantify the levels of speciﬁc aggrecan fragments generated by
aggrecanase-mediated cleavage at the 373Glue374Ala bond within the aggrecan interglobular domain.
Methods: The ELISA employs a commercially available monoclonal antibody to capture aggrecan fragments containing keratan sulfate (KS).
Aggrecan fragments generated by cleavage at the GlueAla bond were then detected using a monoclonal neoepitope antibody (mAb OA-1)
that speciﬁcally recognizes the N-terminal sequence ‘ARGSVIL’.
Results: The mAb OA-1 antibody was highly speciﬁc for the immunizing neoepitope peptide since neither peptides spanning the cleavage site
nor mutated peptides were detected. Aggrecan fragments generated by ADAMTS-4 digested human aggrecan monomers and from IL-1-stim-
ulated human cartilage explants were quantiﬁed by the ELISA, and we observed increased sensitivity of the ELISA compared to mAb OA-1
Western analysis. We also observed that the basal, as well as IL-1-stimulated production of ARGS aggrecan fragments from human articular
cartilage explants was blocked by a selective aggrecanase inhibitor, consistent with generation of the ARGS neoepitope in human articular
cartilage being mediated by aggrecanase. Using puriﬁed human aggrecan digested by ADAMTS-4 as standard to quantify ARGS aggrecan
fragments in human synovial ﬂuids, we determined that the calculated amount of ARGSVIL-aggrecan fragments by ELISA measurement is in
agreement with the published levels of these fragments, supporting its potential utility as a biomarker assay for osteoarthritis.
Conclusion: We have developed an assay that detects and quantiﬁes speciﬁc aggrecan fragments generated by aggrecanase-mediated
cleavage. Because aggrecanase mediates degradation of human articular aggrecan in joint disease, the KS/mAb OA-1 ELISA may serve
as a biomarker assay for evaluation of preclinical and clinical samples.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Onset and progression of joint destruction in osteoarthritis
(OA) often occurs in the absence of clinical symptoms.
This results in a delay of diagnosis and has hampered the
monitoring of disease progression and development of dis-
ease-modifying agents. For this reason, several assays
have been developed that quantify matrix molecule frag-
ments and other molecules associated with the turnover
and breakdown of joint cartilage matrix in body ﬂuids1e4.
In general, many of the currently used assays lack spec-
iﬁcity for the particular fragment(s) detected or the process
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Received 7 June 2005; revision accepted 24 January 2006.7generating them. Immunoassays that rely on the detection
of a neoepitope generated through proteolytic substrate
cleavage can provide information on the activity of a speciﬁc
proteolytic pathway. Such information is particularly valu-
able for the monitoring of disease-modifying therapy of
OA and other joint diseases, for which proteolytic inhibitors
are being developed5e9. For example, the degradation of
type II collagen in cartilage in vivo generates different types
of fragments. These presumably result from the action of
several different proteases, including MMP-13, which are
capable of cleaving in the telopeptide domains10e13. The
collagen fragment families can be detected in urine, blood
and synovial ﬂuid by assays speciﬁc for the different neoe-
pitope sequences10,14e16 and have shown promise in sev-
eral animal models of cartilage degradation17,18. Such
assays may then allow the monitoring of particular proteo-
lytic activities, which can then be related to treatment,
drug levels, disease activity and prognosis. However,02
703Osteoarthritis and Cartilage Vol. 14, No. 7currently used assays for aggrecan detection generally lack
speciﬁcity for the particular fragment(s) or information relat-
ing to the biochemical process that resulted in their
generation.
A critical role for the aggrecanases, including ADAMTS-4
and ADAMTS-5, in aggrecan degradation in arthritis is sup-
ported by the identiﬁcation of aggrecan fragments with an
N-terminus consisting of 374ARGSVIL in the synovial ﬂuid
from human OA patients19e21. Consistent with this observa-
tion, studies in bovine explant cultures suggest that IL-1
stimulated aggrecan degradation is mediated through an
aggrecanase-dependent pathway, since the generation of
similar neoepitopes can be inhibited by selective aggreca-
nase inhibitors6,22. Using MMP and aggrecanase inhibitors
in human OA cartilage explants, it was further demonstrated
that aggrecanase inhibition was required for aggrecan pro-
tection23. These data support the hypothesis that aggreca-
nase inhibitors may be effective cartilage protectants, and
that a biomarker assay that quantiﬁes aggrecan fragments
with an N-terminus consisting of 374ARGSVIL may be use-
ful. Current assays that measure aggrecan levels lack spec-
iﬁcity for aggrecanase-mediated proteolytic pathways24,25.
Utility of such an assay would not be limited to evaluation
of aggrecanase-generated aggrecan fragments in in vitro
systems, but could also support development of in vivo
models of cartilage degradation and serve as a biomarker
assay to monitor aggrecanase activity in a clinical trial
setting.
We report here the development of an enzyme linked im-
munosorbent assay (ELISA) to quantify speciﬁcally aggre-
canase-generated aggrecan fragments containing keratan
sulfate (KS) and the ARGSVIL neoepitope sequence gener-
ated by the action of aggrecanases. This assay employs
a commercially available anti-KS monoclonal antibody and
a neoepitope antibody against the N-terminal 374ARGSVIL
sequence derived from the interglobular domain of
aggrecan.
Materials and methods
ANTIBODIES
Polyclonal antibodies raised against the aggrecan neoe-
pitope sequence ASTASELE and NITEGE were generated
at Invitrogen (Carlsbad, CA) and Biosource Quality Con-
trolled Biochemicals (QCB) (Hopkinton, MA), respectively26.
A monoclonal antibody (mAb) mAb OA-1, against the se-
quence ARGSVIL, which represents the N-terminus of the
Glu373Y Ala374 interglobular domain cleavage, was devel-
oped at GlaxoSmithKline (GSK). The mAb OA-1 antibody
was generated from hybridomas raised against a synthetic
peptide (ARGSVILTVKGGC)27 conjugated to ovalbumin
(OVA). Brieﬂy, a female SJL mouse (Jackson Laboratories,
Bar Harbor, ME) was immunized six times over 11 days us-
ing the RIMMS method28. On day 13, the mouse was sac-
riﬁced and lymph nodes collected. A single-cell suspension
of lymphocytes was prepared for fusion with myeloma cells
as previously described29. Hybridomas were cloned by lim-
iting dilution method. Immunoglobulin class and subclass
were determined using an ELISA Clonotyping System
(Southern Biotechnology, Birmingham, AL) following the
manufacturer’s instructions. The mAb OA-1 antibody con-
sisted of IgG1 heavy chain and k light chain isotype. Bioti-
nylation of mAb OA-1 was performed using an EZ-Link
Biotinylation kit (PIERCE, Rockford, IL) following the manu-
facturer’s instructions. Speciﬁcity of binding was demon-
strated using immunizing peptides to competitively reducethe binding of the corresponding antibody to its antigen.
Anti-G1 (anti-ATEGQV) rabbit polyclonal antibody was
a kind gift from Dr. John Sandy [Shriner’s Hospital, Tampa,
FL]30.
OTHER MATERIALS
Chondroitinase ABC, keratanase and keratanase II were
purchased from Seikagaku (Associates of Cape Cod, Fal-
mouth, MA), and hyaluronidase was purchased from Sigma
(St. Louis, MO, USA). A protease inhibitor cocktail (COM-
PLETE) was purchased from Roche Molecular Biochem-
icals (Indianapolis, IN), and prepared as recommended by
the manufacturer (1 tablet/50 ml). A 96-well plate containing
a monoclonal antibody that recognizes KS chains was pur-
chased from Biosource International (Camarillo, CA). Strep-
tavidin-HRP was obtained from KPL (Gaithersburg, MD),
and TMB substrate was purchased from Dako (Carpinteria,
CA). The aggrecanase selective inhibitor, SB-703704, and
the broad spectrum MMP inhibitor, CGS-27023A, were syn-
thesized at GSK as described6,31. They were prepared as
10 mM stock solutions in 100% dimethyl sulfoxide
(DMSO). Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) loading, running, and transfer
buffers, 4e12% Triseglycine gradient gels, and DMEM:F12
(1:1) culture media were purchased from Invitrogen
(Carlsbad, CA). PVDF membrane and streptavidin-coated
96-well plates were purchased from Perkin Elmer (Well-
esley, MA). For Western analysis goat anti-rabbit or
anti-mouse IgG linked to HRP was purchased from Cell
Signaling Technology (Beverly, MA), and West Pico chem-
iluminescence detection kit was from Pierce (Rockford, IL).
For testing of mAb OA-1 speciﬁcity by ELISA, biotinylated
peptides were synthesized by American Peptide Company
(Sunnyvale, CA), and goat anti-mouse IgG linked to HRP
was purchased from Calbiochem (EMD Biosciences, Inc.,
San Diego, CA). Alcian Blue 8GS (C.I. no 742240) was
from Chroma-Gesellschaft (Ko¨ngen, Germany). Recombi-
nant human IL-1 alpha was generated at GSK.
mAb OA-1 SPECIFICITY
Peptides containing a C-terminal biotin were evaluated
for mAb OA-1 immunoreactivity following immobilization
on a streptavidin-coated 96-well plate. mAb OA-1 (100 ng/
ml) was added in the presence of 1% w/v BSA/PBS/
0.05% v/v Tween-20. Bound mAb OA-1 was detected with
a goat anti-mouse IgG linked to HRP (Calbiochem). TMB
was used as substrate and absorbance was monitored at
630 nm. Data are presented as the mean of four replicates,
and standard error of the mean was calculated.
AGGRECAN DIGESTS
Full length human recombinant ADAMTS-4 was cloned,
expressed and puriﬁed at GSK32. Human aggrecan mono-
mers (A1D1) were isolated and puriﬁed from cartilage33
pooled from several donors obtained from autopsy (Na-
tional Disease Research Interchange, Philadelphia, PA,
USA), or from joint replacement (University of Pennsylva-
nia, Philadelphia, PA, USA). Cartilage was isolated from
the tibial plateau, femoral condyle, and the patellar groove.
All human tissue was obtained with informed consent and
was used under the approval of the institutional review
board (IRB). Unless otherwise noted, human aggrecan
monomers were quantiﬁed based on dry weight.
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ous concentrations of the selective aggrecanase inhibitor,
SB-703704, was incubated with puriﬁed human aggrecan
monomers (333 nM, assuming a molecular weight of full
length aggrecan of 1.5 106 Da) for the times indicated in
ﬁgure legends at 37(C in 50 mM TriseHCl, 100 mM NaCl,
and 10 mM CaCl2, pH 7.5. The corresponding DMSO con-
centration in the digests introduced with compound was
never higher than 0.01%, and at this DMSO concentration,
had no direct effects on enzyme activity (data not shown).
Digests were quenched with 20 mM EDTA. Prior to Western
or ELISA analysis, aggrecan was deglycosylated with chon-
droitinase ABC (0.1 unit/10 mg aggrecan dry weight) for 2 h
at 37(C in 100 mM Tris/HCl pH 8.0 containing a protease
inhibitor mixture (COMPLETE). Samples for Western
analysis were further deglycosylated with keratanase
(0.1 unit/10 mg) and keratanase II (0.002 unit/10 mg) for an
additional 2 h at 37(C in 100 mM sodium acetate pH 6.0
containing a protease inhibitor mixture described above,
and were concentrated with ice cold acetone prior to sepa-
ration by SDS-PAGE.
HUMAN CARTILAGE EXPLANTS
Cartilage was graded normal based on a modiﬁed Col-
lin’s score34. Explants from a single donor were prepared,
weighed, and treatments were applied in the presence of
DMEM:F12 with 0.5% heat inactivated fetal calf serum
(80 mg cartilage/ml media). After 7 days, conditioned media
were removed and replaced with fresh treatments, and the
cultures were incubated for an additional 7 days. Recombi-
nant human IL-1 alpha was used at a concentration of
100 ng/ml. The aggrecanase selective inhibitor, SB-
703704, and the broad spectrum MMP inhibitor, CGS-
27023A, were each tested at 10 mM. The corresponding
DMSO concentration in the cultures introduced with com-
pound was never higher than 0.1%, and at this DMSO con-
centration, had no direct effects on IL-1 stimulation in
separate studies (data not shown).
HUMAN SYNOVIAL FLUIDS
Human synovial ﬂuids were obtained from patients with
joint injury or arthritis, after informed consent and IRB ap-
proval. Analysis of synovial ﬂuids was based on volume.
For KS/mAb OA-1 ELISA analysis, synovial ﬂuids were ﬁrst
treated with an equal volume containing ﬁve turbidity reduc-
ing units of Streptomyces hyaluronidase in 100 mM sodium
acetate pH 6 containing 20 mM EDTA and 0.5 mM AEBSF
for 3 h at 60(C as described21, diluted in 1% w/v BSA in
PBS/Tween 20 (0.05%), and then analyzed by ELISA as
described. For Western analysis, aggrecan from synovial
ﬂuids was ﬁrst isolated by Alcian Blue precipitation35, fol-
lowed by Western analysis as described.
AGGRECAN CAPTURE ELISA
Following deglycosylation with chondroitinase ABC,
aggrecan (100 ng dry weight/well), conditioned media from
human articular cartilage explants (2 ml from the 1 ml total
conditioned media generated at each time point), or the
equivalent of 0.25e5 ml of human synovial ﬂuid were incu-
bated (in the presence of 1% w/v BSA in PBS/Tween 20
(0.05% v/v)) for 2 h at 25(C on a 96-well plate (Biosource)
containing a monoclonal antibody that recognizes KS
chains and, according to the manufacturer, is not impactedby other non-KS glycosaminoglycans (GAGs), including hy-
aluronic acid, chondroitin sulfate, and heparin sulfate. Frag-
ments containing ARGSVIL neoepitope were detected
using biotinylated mAb OA-1 (600e1200 ng/ml). Levels of
bound biotinylated mAb OA-1 were detected using 1 mg/
ml streptavidin-HRP and TMB as substrate. Absorbance
readings following acidiﬁcation were determined in a micro-
plate reader at a wavelength of 450 nm. Data are presented
as the mean and standard deviation of 2e3 replicates per
data point. In several preliminary experiments, we evalu-
ated human aggrecan monomer digested by ADAMTS-4
to determine the optimum amount of aggrecan fragments
that could be detected in the ELISA. We loaded the equiv-
alent of 10e1000 ng of human aggrecan monomer and de-
termined that the best signal:noise ratio between
undigested and ADAMTS-4 digested aggrecan was ob-
served with 100 ng of puriﬁed monomer (data not shown).
Although all the ELISA data presented in this report are
based on chondroitinase ABC digestion of ELISA samples,
it was determined that chondroitinase ABC digestion was
not required for detection of ARGSVIL-aggrecan generated
from ADAMTS-4-digested human aggrecan monomers
(data not shown).
WESTERN ANALYSIS
Aggrecan digests (2e10 mg loaded per well), conditioned
media (20 ml from the 1 ml total conditioned media gener-
ated at each time point) from human articular cartilage, or
25 ml of human synovial ﬂuid (following Alcian Blue precipi-
tation35) were deglycosylated with chondroitinase ABC, ker-
atanase, and keratanase II, separated on a 4e12%
Triseglycine gradient gel, and transferred overnight to
PVDF membrane. Membranes were blocked with 5% w/v
non-fat dried milk in PBS/0.05% v/v Tween 20, and then
probed with the speciﬁc antibody in blocking buffer. The fol-
lowing primary antibody concentrations were used: anti-TA-
SELE: 1 mg/ml; mAb OA-1: 2e5 mg/ml; anti-NITEGE:
1:2000 dilution, and anti-G1: 1:5000 dilution. Immunoreac-
tive proteins were detected with goat anti-rabbit or mouse
IgG linked to HRP (Cell Signaling Technology, Beverly,
MA), followed by chemiluminescence detection.
GAG ASSAY
Conditioned media were analyzed for the levels of GAG
by DMMB colorimetric assay, using shark chondroitin sul-
fate as standard36. Values are presented as mg GAG per
mg cartilage wet weight. GAG concentrations in synovial
ﬂuids were determined by Alcian Blue precipitation35.
Results
SPECIFICITY OF mAb OA-1 MONOCLONAL ANTIBODY
mAb OA-1 monoclonal antibody was generated from
a mouse immunized with a peptide-OVA conjugate, con-
taining an N-terminus 374ARGSVIL sequence from the inter-
globular domain of human aggrecan. The antibody was
tested for its ability to detect peptides consisting of various
sequences immobilized on a streptavidin coated 96-well
plate in an ELISA format (Table I). The N-terminal alanine
was critical for recognition by mAb OA-1, as scrambling
(peptide 29, Table I), removal (peptide 30), or addition of
amino acids from the aggrecan core protein (peptides 31,
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gest that 375R (based on human aggrecan sequencea) is
also critical, as substitution of Arg by Leu as in murine ag-
grecan, results in a loss of recognition (peptide 25). Substi-
tution of Ser377 to either an Asn (peptide 22, 26, and 27) or
a Thr (peptide 28) was well tolerated. Peptide 22 was de-
signed to address a speciﬁc point mutation at position 377
present in horse, rat, and guinea pig, i.e., Ser377 to aspara-
gine, and peptide 23 was designed to address a speciﬁc
point mutation at position 382 present in several species in-
cluding horse and rat, i.e., Val382 to alanine. Mutations at
these respective sites had minimal effects on OA-1 reactiv-
ity. However, substitutions of Val378 with Ile and/or the I379
with Ala (peptide 24) were not acceptable. These data sug-
gest that mAb OA-1 is a highly speciﬁc monoclonal antibody
for the detection of the ARGSVIL sequence in aggrecan.
Aggrecan from a number of species, including guinea pig,
horse, rat, and pig, may also present a suitable epitope
for mAb OA-1.
HUMAN AGGRECAN MONOMER DIGESTION BY ADAMTS-4
Western analysis of human aggrecan monomers follow-
ing digestion by ADAMTS-4 (Fig. 1) was used to demon-
strate the reactivity of mAb OA-1 monoclonal antibody to
the ARGSVIL sequence. No immunoreactive fragments
were detected in the intact substrate preparations (lane
1). Several mAb OA-1-reactive fragments were generated
after only a 1 h ADAMTS-4 digestion (lane 2), and this
was associated with the concomitant appearance of NI-
TEGE reactive fragments (data not shown). Putative iden-
tity of the 250 kDa product based on Western analysis
using an antibody to another aggrecanase cleavage site,
the TASELE neoepitope, is consistent with aggrecanase
cleavage at this site (data not shown)26. However, identity
of the C-terminus of the 140 kDa fragment is difﬁcult to as-
sign, since no aggrecanase cleavage site between the G2
domain and the TASELE site has been identiﬁed. Another
explanation is that the substrate used in these studies con-
tains a heterogeneous population of G1-containing
Table I
Specificity of mAb OA-1 Monoclonal Antibody. C-terminal biotiny-
lated peptides were immobilized onto a streptavidin-coated 96-
well plate, and mAb OA-1 (100 ng/ml) was added. HRP conjugated
goat anti-(mouse IgG) and TMB was used for detection at 630 nM.
SE: standard error of the mean
Peptide No. Sequence Mean absorbance
at 630 nm (SE)
34 ARGSVILTVK-biotin (human) 0.885 (0.15)
22 ARGNVILTVK-biotin 0.651 (0.02)
23 ARGSVILTAK-biotin 0.983 (0.12)
24 ARGSIATGK-biotin (chicken) 0.004 (0)
25 ALGSVILTAK-biotin (mouse) 0
26 ARGNVIHTVK-biotin (guinea pig) 1.096 (0.06)
27 ARGNVILTAK-biotin (horse, rat) 1.026 (0.17)
28 ARGTVILTVK-biotin (porcine) 0.623 (0.03)
29 RAGSVILTVK-biotin 0
30 RGSVILTVK-biotin 0.013 (0)
31 GEARGSVILTVK-biotin 0.002 (0)
32 EARGSVILTVK-biotin 0.004 (0)
35 EGEARGSVILTVK-biotin 0
aThe human aggrecan residue numbers used in this paper were
obtained by subtraction of 19 amino acids (leader sequence) from
the total (1-2415 amino acid) sequence of human aggrecan
(NCBI accession No. P16112).aggrecan characterized by C-terminal truncation and pre-
sumably generated in situ. Consistent with this hypothesis,
analysis of the aggrecan monomers used as substrate by
anti-G1 Western analysis suggests that a diffuse band of
proteins was present that migrated near the 250 kDa
marker (data not shown). mAb OA-1 immunoreactivity
against these fragments was blocked by co-incubation
with an immunizing peptide consisting of the sequence
ARGSVIL (lane 3), but not with a peptide with a scrambled
N-terminus, RAGSVIL (lane 4). The antibody did not detect
aggrecan fragments generated by MMP-3 digestion (data
not shown). These results suggest that mAb OA-1 is highly
speciﬁc and is suitable for detection of aggrecanase-gener-
ated aggrecan fragments by Western analysis.
ANALYSIS OF ADAMTS-4 DIGESTS BY ANTI-KS/mAb OA-1
SANDWICH ELISA
ELISA plates pre-coated with a monoclonal antibody
against KS were used to capture KS-containing fragments
from human aggrecan digests. From this captured pool,
the ARGSVIL-containing aggrecan fragments generated
by ADAMTS-4 cleavage were detected with mAb OA-1.
Since both capture and detection antibodies were monoclo-
nals, mAb OA-1 was biotinylated allowing us to employ
a streptavidin-HRP reporter to amplify and detect mAb
OA-1 immunoreactivity.
Human recombinant ADAMTS-4 (17 nM) was incubated
with human aggrecan monomers (333 nM), and at the times
indicated in Fig. 2, samples were removed, quenched with
EDTA, and deglycosylated with chondroitinase ABC. The
samples were then analyzed by anti-KS/mAb OA-1 sand-
wich ELISA (Fig. 2). A time-dependent increase in ARGS-
VIL-containing aggrecan fragments was generated by
ADAMTS-4, which appeared to reach a plateau after 1 h.
No increase of ARGSVIL-aggrecan fragments was detected
when mAb OA-1 was co-incubated with the immunizing
peptide ARGSVIL, suggesting that binding was speciﬁc.
Reactivity was also inhibited by co-incubation of
ADAMTS-4 with a selective aggrecanase inhibitor, SB-
703704.
To test the responsiveness of the ELISA, we generated
ARGSVIL-containing fragments of aggrecan from a series
of digests generated with ADAMTS-4 in the presence of
various concentrations of the aggrecanase inhibitor, SB-
703704. The products were then analyzed by both mAb
OA-1 Western and anti-KS/mAb OA-1 sandwich ELISA
(Fig. 3). Based on mAb OA-1 Western analysis, the inhibitor
caused a concentration-dependent reduction in the genera-
tion of ARGSVIL-containing aggrecan fragments, with an
IC50 estimated to be between 10 and 60 nM. The same
samples were also analyzed by ELISA, and a similar con-
centration dependent inhibition was observed, consistent
with data generated by Western. The IC50 of SB-703704
was extrapolated from a concentration response curve gen-
erated in the ELISA and calculated to be approximately
30 nM; this value is consistent with the level of inhibition ob-
served in the OA-1 Western analysis. Aggrecan fragments
generated in 15 min using ADAMTS-4 concentrations as
low as 2 nM could be detected by ELISA, whereas under
the same loading conditions used in the inhibitor study,
these same samples were difﬁcult to visualize by Western
analysis (data not shown). The production of ARGSVIL
fragments detected by the ELISA was linear with respect
to time using ADAMTS-4 concentrations as low as
2e4 nM (data not shown), and the Z0 (an assay quality
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Fig. 1. Western analysis with mAb OA-1 of ADAMTS-4 digested aggrecan monomers. Human aggrecan monomers were incubated for 1 h in
the absence or presence of 8 nM ADAMTS-4, and samples (2 mg GAG) were analyzed by mAb OA-1 (2 mg/ml) Western. Lane 1, undigested
aggrecan; lanes 2, 3 and 4, aggrecan digested with ADAMTS-4. Lanes 1 and 2, no peptide addition; lane 3, addition of 1 mM ARGSVIL pep-
tide; and lane 4, addition of 1 mM RAGSVIL peptide. Putative identities of ARGSVIL fragments are indicated.indicator which incorporates the variability of the data and
the signal window of the assayb,37) of the assay under these
conditions, was >0.75, suggesting that the assay was ro-
bust and suitable to distinguish between treatments. The
anti-KS/mAb OA-1 sandwich ELISA correlates with and is
more sensitive than mAb OA-1 Western analysis.
ANALYSIS OF CONDITIONED MEDIA FROM HUMAN CARTILAGE
EXPLANTS BY KS/mAb OA-1 SANDWICH ELISA AND WESTERN
IMMUNOBLOT
To characterize the results of aggrecanase activity in hu-
man articular cartilage, explants were prepared from articu-
lar cartilage graded as ‘normal‘, and were stimulated for 1
week with IL-1 (100 ng/ml) to induce aggrecan degradation.
At the end of the culture period, the media from the cartilage
explants were collected, and analyzed for GAG levels by
DMMB assay, and by mAb OA-1 Western analysis and
anti-KS/mAb OA-1 ELISA. The increase in ARGSVIL aggre-
can fragments induced by IL-1 was associated with a two-
fold increase in overall GAG release from the tissue (con-
trol: 1.6 mg/mg and IL-1: 3.2 mg/mg).
Consistent with the involvement of aggrecanase in the gen-
eration of the ARGSVIL aggrecan fragments from IL-1-stimu-
lated human cartilage, the ARGSVIL fragment pattern in the
conditionedmediawas similar to that generated by human ag-
grecan monomers digested for 0.25 or 2 h by ADAMTS-4,
generated using a higher concentration of enzyme (17 nM)
and loading a greater amount of aggrecan starting material
per lane (10 mg/lane) than in previous ﬁgures (Fig. 4).
To examine if the in vitro production of ARGSVIL-contain-
ing aggrecan fragments was sensitive to aggrecanase inhibi-
tion, explant incubation was performed in the absence or
presence of SB-703704 (Fig. 5), a selective aggrecanase in-
hibitor, and compared to that of a broad spectrumMMP inhib-
itor, CGS-27023A, that has poor aggrecanase inhibitory
activity (data not shown). Although the human joint cartilage
was graded ‘normal’ based on visual appraisal, there were
mAbOA-1-reactive fragments released from the cartilage af-
ter the ﬁrst 7 days in culture [Fig. 5(A), lane 1]. Interestingly,
these fragments were not detected during the second week
bZ 0 ¼ 1[3(SD highþSD low)/(Avg highAvg low)] where Avg
high represents the positive, Avg low represents the control, and
SD is the standard deviation of the Avg high and Avg low values37.of culture [Fig. 5(B), lane 5]. There are several possible ex-
planations for these observations, including but not limited
to the presence of endogenous active aggrecanase prior to
tissue isolation, or the activation of aggrecanase during early
stages of tissue incubation. In support, human cartilage ex-
plants derived from several different donors showed a base-
line level of aggrecan degradation in unstimulated cartilage
that was attenuated by the addition of SB-703704 (unpub-
lished observation). Similar to articular cartilage from other
species, IL-1 appeared to induce aggrecan degradation in
human cartilage [Fig. 5(A and B), lanes 2 and 6]. Aggrecan
degradation was blocked by the aggrecanase inhibitor, SB-
703704 (10 mM) [Fig. 5(A and B), lanes 3 and 7], to below
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Fig. 2. Anti-KS/mAb OA-1 sandwich ELISA analysis of aggrecan
digestion by ADAMTS-4. Human aggrecan monomers (333 nM)
were incubated with ADAMTS-4 (17 nM) in the presence or
absence of aggrecanase inhibitor SB-703704 (1 mM). At the times
indicated, samples (100 ng) were removed, quenched, deglycosy-
lated with chondroitinase ABC, and analyzed by anti-KS/mAb
OA-1 sandwich ELISA. Immunoreactivity was blocked by co-incu-
bation with immunizing peptide ARGSVIL (1 mM).
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Fig. 3. Correlation between anti-KS/mAb OA-1 sandwich ELISA and mAb OA-1 Western analysis based on concentration response of aggre-
canase inhibitor SB-703704 on ADAMTS-4 digestion of aggrecan monomers. ADAMTS-4 (4 nM) was incubated in the absence or presence of
various concentrations of SB-703704, and digestion of human aggrecan monomers (333 nM) was allowed to proceed for 1 h. Samples were
analyzed in both anti-KS/mAb OA-1 sandwich ELISA and mAb OA-1 Western blot (2 mg/lane).the baseline level present in unstimulated cartilage, which
supports the hypothesis that the initial baseline release of
aggrecanase-generated aggrecan fragments was the result
of endogenous aggrecanase activity prior to IL-1 stimulation.
TheMMP inhibitor caused only a slight attenuation of ARGS-
VIL-aggrecan fragment generation after IL-1 stimulation,
consistent with its poor aggrecanase inhibitory activity
[Fig. 5(A and B), lanes 4 and 8].
The same samples were then analyzed in the anti-KS/
mAb OA-1 sandwich ELISA (Fig. 5). Observations made us-
ing the ELISA were consistent with those using mAb OA-1
Western analysis. A high level of mAb OA-1 reactive mate-
rial was present in the 0e7 day conditioned media from un-
stimulated cartilage, but was reduced in the 7e14 day
media. IL-1 caused an increase in immunoreactive frag-
ments that was clearly observed in media generated during
days 7e14. The aggrecanase inhibitor SB-703704 was ef-
fective in blocking immunoreactive fragments generated in
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C IL hours20.25
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Fig. 4. Degradation of human cartilage explants in response to IL-1
and digestion of puriﬁed human aggrecan monomers by ADAMTS-
4 results in the generation of comparable aggrecan fragments. Hu-
man articular cartilage explants were either left untreated (C), or
treated with IL-1 (IL) for 7 days and conditioned media were ana-
lyzed by ARGS Western analysis. Human aggrecan monomers
(10 mg GAG) were digested for 0.25 or 2 h with ADAMTS-4
(17 nM) prior to deglycosylation and Western immunoblot.IL-1-stimulated cartilage, while the MMP inhibitor CGS-
27023A was much less effective.
GENERATION OF KS/mAb OA-1 STANDARD USING A TOTAL
ADAMTS-4 DIGEST OF HUMAN AGGRECAN MONOMERS
A complete ADAMTS-4 digest of human aggrecan mono-
mers was prepared and used as a standard for quantiﬁcation
of samples with the anti-KS/mAb OA-1 sandwich ELISA. Ag-
grecan monomer was digested with ADAMTS-4 for 24 h, an
aliquot was removed for Western analysis, and after a sec-
ond ADAMTS-4 addition, the sample was allowed to incu-
bate for an additional 24 h. Samples (5 mg GAG/lane) from
the incubations were evaluated by mAb OA-1 Western anal-
ysis [Fig. 6(A)]. In the absence of ADAMTS-4 digestion, no
ARGSVIL-containing aggrecan fragments were immuno-
detected [Fig. 6(A), labeled ‘undig.’]. The 24 h digestion
resulted in the generation of a ladder of mAb OA-1 reactive
ARGS-fragments (labeled ‘TS-4 24 hr’), and a complete con-
version of the G1-containing starting material to a single
70 kDa G1-NITEGE fragment (data not shown). Further di-
gestion with a fresh aliquot of ADAMTS-4 incubated for an
additional 24 h did not appear to change the ladder of mAb
OA-1-reactive fragments (labeled ‘TS-4 48 hr’), suggesting
that the sample represented a total digest. Further evaluation
of the anti-G1 Western demonstrated that the aggrecan
starting material was fragmented prior to ADAMTS-4 diges-
tion, possibly by C-terminal digestion of the aggrecan mono-
mers in situ. For this reason, the ‘classical’ 250 kDa
ARGSVIL fragment was not detected after a 24 h
ADAMTS-4 digestion. While this aggrecan sample may not
represent a suitable substrate to study digestion of intact ag-
grecan monomer, it represents a suitable standard to use in
the anti-KS/mAb OA-1 sandwich ELISA.
The 48 h sample generated in Fig. 6(A) was analyzed in
the anti-KS/mAb OA-1 sandwich ELISA [Fig. 6(B)]. The
amount of ARGSVIL-aggrecan was estimated based on
the assumption that the sample represented a total digest,
and conversion of the starting material to product resulted
in a 1:1 molar ratio of substrate to ARGSVIL-containing ag-
grecan fragments. A characteristic sigmoidal-shaped con-
centration response curve was generated as increasing
amounts of the ADAMTS-4 aggrecan digest was analyzed
in the anti-KS/mAb OA-1 sandwich ELISA [Fig. 6(B)].
Levels of ARGSVIL-aggrecan present in biological samples
could then be estimated using the equation of the curve
shown at the bottom of the ﬁgure. These results support
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709Osteoarthritis and Cartilage Vol. 14, No. 7the utility of the KS/mAb OA-1 sandwich ELISA to estimate
the levels of aggrecanase-digested aggrecan fragments
present in biological samples over a range of 13e300
fmoles.
EVALUATION OF HUMAN SYNOVIAL FLUIDS IN KS/mAb OA-1
SANDWICH ELISA
The ADAMTS-4-generated aggrecan fragment standard
was used to estimate the levels of ARGSVIL-containing ag-
grecan fragments in synovial ﬂuid isolated from a human
donor (Fig. 7). The amount of synovial ﬂuid analyzed
ranged between 0.25 and 2.5 ml. There was a dose depen-
dent increase in immunoreactivity associated with in-
creased synovial ﬂuid volume tested. In a separate study,
immunoreactivity of the sample reached a plateau between
2.5 and 5 ml (data not shown). A similar synovial ﬂuid dose
range was evaluated in the presence of ARGSVIL immuniz-
ing peptide, and the peptide was shown to block the overall
immunoreactivity of the sample (data not shown), and was
therefore used as a background control. Immunoreactivity
of human synovial ﬂuid was not impacted by peptide con-
sisting of the scrambled N-terminus (RAGSVIL), suggesting
that detection was speciﬁc (data not shown).
We next determined if the quantitation of ARGSVIL-con-
taining fragments by KS/mAb OA-1 ELISA correlated with
an independent measure of GAG. For this purpose, we
selected additional synovial ﬂuid from several independent
human donors and determined their GAG content by Alcian
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Fig. 7. Analysis of human synovial ﬂuid in KS/mAb OA-1 sandwich
ELISA. Human synovial ﬂuid (0.25e2.5 ml) was digested with hyal-
uronidase, chondroitinase ABC, and then evaluated in the KS/mAb
OA-1 sandwich ELISA. Binding was demonstrated to be speciﬁc by
blocking with immunizing peptide (1 mM ARGSVIL), and not by pep-
tide with scrambled N-terminus (1 mM RAGSVIL) (data not shown).
A background control at each data point representing the absor-
bance values evaluated in the presence of immunizing peptide
(1 mM ARGSVIL) was subtracted from the absorbance of each
sample, and the resulting values were used to calculate the level
of ARGSVIL-aggrecan (in fmoles) based on a standard curve sim-
ilar to that shown in Fig. 6. Data are presented as the mean and
standard deviation of duplicate samples.Blue precipitation assay. These samples (1 ml) were then
evaluated in the ELISA, and the level of ARGSVIL-contain-
ing aggrecan fragments estimated based on a standard
curve of the ADAMTS-4 total digest similar to that shown
in Fig. 6. The synovial ﬂuid levels of ARGSVIL-aggrecan
present in several representative human donor samples
are presented graphically in Fig. 8(A), and the correspond-
ing GAG concentrations are shown at the bottom of the ﬁg-
ure. The ARGSVIL-aggrecan levels detected in the selected
synovial ﬂuids ranged from only 50 to 100 pmoles/ml,
whereas the GAG levels in each of these samples varied
from 56 to 475 mg/ml. Sample 2019-1, which had no detect-
able ARGSVIL-aggrecan had the lowest GAG concentra-
tion of the samples shown in Fig. 8(A). However, other
samples with GAG concentrations as high as 166 mg/ml
did not contain detectable levels of ARGSVIL-aggrecan
(data not shown). Therefore, it appears that although sam-
ples that have detectable levels of ARGSVIL epitope also
have measurable GAG levels, a good correlation does not
exist between these two independent measurements based
on this limited dataset. Several of these samples were then
evaluated by Western blot analysis with mAb OA-1 antibody
[Fig. 8(B)]. Consistent with their anti-KS/mAb OA-1 ELISA
results in Fig. 8(A), there were detectable ARGSVIL-con-
taining aggrecan present in the two ELISA positive synovial
ﬂuids (donor 3657-1, 2639-1). There were no detectable
fragments present in synovial ﬂuid derived from donor
2019-1 either by Western analysis [Fig. 8(B)] or by ELISA
[Fig. 8(A)]. These results support the utility of the KS/mAb
OA-1 sandwich ELISA to estimate the levels of aggreca-
nase-digested aggrecan fragments present in human syno-
vial ﬂuids.
Discussion
Cartilage matrix contains two major protein components,
type II collagen and aggrecan. Proteolytic destruction of
type II collagen and aggrecan and resulting loss from matrix
ultimately leads to the cartilage loss observed in OA. While
MMPs are believed to contribute to the degradation of type
II collagen, several lines of evidence support a signiﬁcant
contribution of aggrecanase to degradation of aggrecan,
and efforts to block the activities of both these classes of
proteases are under intense investigation. Studies using
bovine explant cultures suggest that IL-1-stimulated aggre-
can degradation is mediated through an aggrecanase-
dependent pathway, based on aggrecan fragments
generated in response to IL-1 and their inhibition by aggre-
canase-selective inhibitors6,22. Similar observations were
made in the human cartilage studies shown herein, and
are consistent with earlier reports19,20,42. In the present
study, we also show that: (1) macroscopically normal hu-
man joint cartilage contained protease activity that was sen-
sitive to an aggrecanase inhibitor; (2) IL-1 induced a similar
activity in vitro that was also blocked by the aggrecanase
inhibitor; and (3) the ladder of aggrecan fragments in IL-
1-stimulated human cartilage in vitro was similar to that of
isolated human aggrecan digested with recombinant
ADAMTS-4. Together, these data suggest that aggreca-
nase is largely responsible for aggrecan degradation in hu-
man cartilage, and underscores the utility of assays that can
speciﬁcally measure aggrecanase-generated fragments.
Although detection of biomarkers such as HA, COMP and
KS in blood may provide supportive evidence of changes in
cartilage matrix turnover, they do not necessarily represent
a speciﬁc proteolytic pathway. To monitor the effects of
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Fig. 8. Analysis of various human synovial ﬂuids in KS/mAb OA-1 sandwich ELISA, OA-1 Western and GAG analyses. Human synovial ﬂuid
(1 ml) from several donors was digested with hyaluronidase, chondroitinase ABC, and evaluated in the KS/mAb OA-1 sandwich ELISA (A).
Levels of ARGSVIL fragments (fmoles) were estimated based on the calculation described in Fig. 7, and are presented as the mean and stan-
dard deviation of duplicate samples (ND: none detected). GAG levels were estimated by Alcian Blue precipitation35, and are shown at the
bottom of the ﬁgure. Synovial ﬂuids from selected donors (25 ml) were Alcian Blue precipitated, digested with chondroitinase ABC, keratanase,
and keratanase II, and analyzed by mAb OA-1 Western analysis (B).compounds that inhibit MMPs as well as aggrecanases it is
important to be able to monitor the speciﬁc proteolytic path-
ways and their effects on speciﬁc matrix components such
as type II collagen and aggrecan. We have generated a spe-
ciﬁc, sensitive monoclonal neoepitope antibody that detects
the N-terminal sequence ARGSVIL from aggrecanase-di-
gested puriﬁed aggrecan monomers, and from conditioned
media of IL-1 induced human cartilage explants. The anti-
body appears to detect similar aggrecan fragments as the
BC-3 antibody27, but no quantitative assay based on the
BC-3 antibody has yet been reported. Because the KS/
mAb OA-1 sandwich ELISA employs a 96-well format, mul-
tiple samples and replicates can be analyzed to increase
the robustness and throughput of the assay.
Speciﬁcity of mAb OA-1 was demonstrated using pep-
tides of different sequences derived from the classical ag-
grecanase interglobular domain cleavage site at
NITEGE373e374ARGSVIL. A peptide with the sequence of
ARGSVIL was readily detected; however, addition of a sin-
gle amino acid at the N-terminus corresponding to Glu373,
or scrambling of the N-terminus from AR to RA, resulted
in a loss of immunoreactivity. Data generated with the use
of peptides derived from aggrecan sequences from different
species suggested that mAb OA-1 would also be suitable to
detect similar aggrecan fragments from a number of spe-
cies in which there were subtle changes in the sequence
ARGSVIL, including pig, horse, rat, and guinea pig. Thus
a major utility of mAb OA-1 would be to allow for evaluation
of these speciﬁc aggrecan fragments generated in a number
of classical in vivo models with these species38e40. How-
ever, the antibody does not detect this sequence in mouse,
most likely due to a 375R/ L substitution in the mouse se-
quence. Since the ELISA relies on KS which is low or ab-
sent both in rat and mouse aggrecan, it might not be
possible to use this ELISA for these species41.
A limitation of the ELISA in its current format is that it may
enrich certain KS populations and compete with those con-
taining the ARGSVIL neoepitope. While we can’t rule out
this possibility occurring, two lines of evidence suggest
that the ELISA in its current format is highly speciﬁc for
ARGSVIL-containing aggrecan and is not severely impaired
by other KS contaminants that may be present in biologicalsamples. The ﬁrst is shown in Fig. 3, demonstrating West-
ern and ELISA analyses of an ADAMTS-4 digestion of pu-
riﬁed human aggrecan in the presence of the
aggrecanase inhibitor. There was a correlation between de-
tection by ELISA and by Western analysis, suggesting that
aggrecan which did not contain ARGSVIL neoepitope, i.e.,
intact aggrecan in the sample, did not severely impact the
detection of the ARGSVIL-aggrecan population. A second
piece of evidence is shown in Fig. 8. Human synovial ﬂuid
samples may contain a variety of unknown proteins that
could possess KS and thus become captured and compete
with ARGSVIL-containing aggrecan. However, based on
a limited dataset, there appeared to be a good correlation
between ELISA and Western detection, suggesting that
KS-containing contaminants in human synovial ﬂuid did
not severely impact our ability to detect ARGSVIL-aggrecan
fragments present in the samples. A solution to circumvent
this concern would be to capture with the OA-1 monoclonal,
and then detect with the anti-KS antibody. In this way, only
ARGSVIL-containing aggrecan would be captured and de-
tected. However, early efforts during the development of
the ELISA suggested that immobilization and capture by
OA-1 would not represent a suitable path forward, and
those efforts were discontinued in favor of the current
format.
Another possible limitation with this ELISA is that not all
ARGSVIL-containing aggrecan fragments may contain
a suitable KS content to become captured. Presumably
large MW ARGSVIL-aggrecan fragments (>140 kDa) that
include the KS rich region between G2 and G3 would be
candidates that would capture. However, smaller ARGSVIL
fragments, like those in Figs. 4e6 (40e60 kDa) may not be
detected. A previous report indicated that bovine aggrecan
contains KS substitution within the IGD, as well as in the KS
rich region between G2 globular domain and the chondroitin
sulfate rich region43. Therefore, potentially smaller MW
ARGSVIL-aggrecan fragments, including those in the
40e60 kDa range, could be captured in the ELISA. Identiﬁ-
cation of those fragments captured would require further
investigation.
Quantitation of these fragments was accomplished
by generating a standard curve using human aggrecan
711Osteoarthritis and Cartilage Vol. 14, No. 7digested with ADAMTS-4. This approach relies on the
assumption that ADAMTS-4 digestion of human aggrecan
is complete and results in the generation of a molar equiv-
alent of aggrecan fragments containing the ARGSVIL neo-
epitope. A complete digest of aggrecan by ADAMTS-4 was
evident since a second addition of the enzyme did not result
in any discernible change in the aggrecan degradation pat-
tern (Fig. 6). This allowed us to quantitate these speciﬁc
fragments in biological ﬂuids. Assay of synovial ﬂuids from
several human donors suggested that the ELISA, in its cur-
rent format, is effective in speciﬁcally detecting aggreca-
nase-generated aggrecan fragments. This was particularly
evident when comparing the levels of aggrecan fragments
by ELISA, Western analysis and independent GAG
measurements.
Synovial ﬂuid samples that had detectable levels of
ARGSVIL-aggrecan also contained measurable GAG
levels. However, the reverse was not always true, since
a few samples with measurable GAG by Alcian Blue pre-
cipitation assay contained no detectable ARGSVIL-aggre-
can. Within this very limited dataset there was not a
strong positive correlation between GAG content and
ARGSVIL-aggrecan levels. Several possible reasons may
account for these apparent discrepancies. First, the Alcian
Blue assay method may detect GAG not present in aggre-
can fragments. Second, GAG-containing aggrecan frag-
ments detected by the Alcian Blue method may not fulﬁll
the necessary combined criteria of having the N-terminal
sequence of ARGSVIL and carrying a complement of KS
chains detected by the anti-KS antibody used. Such a het-
erogeneous population of aggrecan fragments of which only
a subset possess the ARGSVIL neoepitope may result from
the action of other proteases in addition to aggrecanase.
Based on the generation of the total ADAMTS-4/aggrecan
digest presented in Fig. 6, further processing resulting in
the loss of the ARGSVIL neoepitope is probably not due
to aggrecanase, since there was not an appreciable change
in the ARGSVIL-fragment pattern upon introduction of
a fresh aliquot of ADAMTS-4 to the 24 h aggrecan digest.
However, other proteases, including MMPs, and cysteine
and serine proteases may play a role in further degrading
the aggrecanase-generated ARGSVIL-aggrecan frag-
ments. Yet another possibility is that alternative, aggreca-
nase-independent, degradative pathways contribute to
some portion of cartilage aggrecan degradation. We have
recently identiﬁed aggrecan fragments in human synovial
ﬂuids generated by MMP cleavage at the 341Asne342Phe
bond within the aggrecan interglobular domain44. Proteoly-
sis in the vicinity of this site could also be generated by
other proteases, such as cathepsins45,46 and calpains47.
All these processes could inﬂuence the relationship be-
tween synovial ﬂuid GAG and ARGSVIL-aggrecan content.
Interestingly, the calculated values of ARGSVIL-aggrecan
fragments in synovial ﬂuids obtained by ELISA in this study
(w50e100 pmoles/ml) are consistent with published re-
ports in several studies (w100 pmoles/ml) based on inde-
pendent measurements19,44, consistent with the ELISA
speciﬁcally detecting ARGSVIL-aggrecan fragments.
In summary, a medium throughput highly speciﬁc sand-
wich ELISA has for the ﬁrst time been developed to detect
aggrecan fragments with an N-terminus consisting of ARGS-
VIL, speciﬁcally generated via an aggrecanase-mediated
proteolytic pathway. The assay detects these fragments in
ADAMTS-4 digests of isolated human aggrecan monomers,
in conditioned media of human articular cartilage explants,
and in human synovial ﬂuids. This neoepitope-speciﬁc
and quantitative assay offers a major advancement overWesterns which are speciﬁc but less quantitative, and
over ‘generic’ fragment ELISAs which may be fragment
speciﬁc and quantitative, but not necessarily speciﬁc for
a proteolytic pathway or cleavage site. The ELISA has con-
siderable potential for monitoring aggrecanase-related joint
cartilage aggrecan degradation in preclinical arthritis
models. Further work, including the use of synovial ﬂuid
samples from well-characterized donors with a variety of
conditions and disease stages, will be needed to establish
the utility of the assay as a biomarker in human joint
disease.
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